SAN DIEGO—Crown Bioscience, the wholly owned subsidiary of Crown Bioscience International, shared new data the other month supporting the immunocompetent models of MuScreen, their large-scale immunotherapy screening platform. MuScreen interrogates a panel of common syngeneic tumor models to support the evaluation of immuno-oncology agents. CrownBio’s syngeneic models feature immunogenomic (sequencing) data, response to standard-of-care agents (including checkpoint inhibitor benchmarking) and immunophenotyping (FACS) analysis. The platform takes a selection of the models and incorporates shared vehicles in high-throughput format for quick, cost-effective results. The resulting data can be used to quantify model-specific efficacy, measure resistance, clarify pharmacodynamic effects and determine potential combination strategies.